Profile data is unavailable for this security.
About the company
Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally.
- Revenue in USD (TTM)0.00
- Net income in USD-5.00m
- Incorporated1994
- Employees--
- LocationProtagenic Therapeutics Inc149 FIFTH AVENUE, SUITE 500NEW YORK 10010United StatesUSA
- Phone+1 (212) 994-8200
- Fax+1 (302) 636-5454
- Websitehttps://protagenic.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enveric Biosciences Inc | 0.00 | -17.46m | 6.56m | 7.00 | -- | 1.26 | -- | -- | -8.15 | -8.15 | 0.00 | 0.7142 | 0.00 | -- | -- | 0.00 | -144.99 | -104.94 | -207.98 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
| eFFECTOR Therapeutics Inc | 0.00 | -35.81m | 6.67m | 14.00 | -- | -- | -- | -- | -17.11 | -17.11 | 0.00 | -1.94 | 0.00 | -- | -- | 0.00 | -144.34 | -- | -- | -- | -- | -- | -- | -- | -- | -17.38 | 1.43 | -- | -100.00 | -- | -58.00 | -- | -- | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -6.59m | 6.70m | 8.00 | -- | 1.58 | -- | -- | -0.441 | -0.441 | 0.00 | 0.2524 | 0.00 | -- | -- | 0.00 | -90.28 | -- | -104.75 | -- | -- | -- | -- | -- | -- | -49.56 | 0.1527 | -- | -- | -- | -112.71 | -- | -- | -- |
| Cadrenal Therapeutics Inc | -100.00bn | -100.00bn | 6.78m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Clever Leaves Holdings Inc | 17.42m | -19.80m | 6.80m | 296.00 | -- | 0.2763 | -- | 0.3901 | -12.57 | -11.38 | 11.11 | 14.02 | 0.418 | 1.69 | 11.03 | 58,841.21 | -47.51 | -23.20 | -58.14 | -26.55 | 37.64 | -- | -113.66 | -207.52 | 1.63 | -3.70 | 0.0479 | -- | 6.14 | -- | 47.63 | -- | -- | -- |
| Processa Pharmaceuticals Inc | 0.00 | -11.12m | 6.94m | 13.00 | -- | 0.6264 | -- | -- | -8.72 | -8.72 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -154.40 | -84.35 | -175.45 | -90.03 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
| Protagenic Therapeutics Inc | 0.00 | -5.00m | 6.96m | -- | -- | 1.90 | -- | -- | -1.15 | -1.15 | 0.00 | 0.8271 | 0.00 | -- | -- | -- | -80.91 | -74.49 | -94.48 | -92.56 | -- | -- | -- | -- | -- | -9.56 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
| AiXin Life International Inc | 4.09m | -2.09m | 7.00m | 207.00 | -- | -- | -- | 1.71 | -0.0836 | -0.0836 | 0.1636 | -0.0765 | 0.8268 | 5.43 | 10.02 | 19,757.49 | -42.27 | -16.93 | -- | -34.54 | 16.25 | 48.13 | -51.12 | -36.96 | 0.1515 | -- | -- | -- | 51.00 | 58.08 | 67.18 | -- | 194.59 | -- |
| Kineta Inc | 5.44m | -14.10m | 7.01m | 11.00 | -- | 2.30 | -- | 1.29 | -1.43 | -1.43 | 0.5297 | 0.278 | 0.3927 | -- | -- | 494,727.30 | -101.57 | -66.16 | -318.39 | -86.61 | -- | -- | -258.65 | -854.74 | -- | -1,310.25 | 0.2011 | -- | 178.65 | 13.89 | 77.76 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -7.00m | 7.01m | 4.00 | -- | 0.7047 | -- | -- | -5.83 | -4.17 | 0.00 | 2.45 | 0.00 | -- | -- | 0.00 | -133.76 | -182.35 | -174.49 | -235.45 | -- | -- | -- | -- | -- | -55.50 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 2.46m | -13.40m | 7.03m | 17.00 | -- | 0.0926 | -- | 2.86 | -131.37 | -131.37 | 20.91 | 26.67 | 0.1831 | 2.41 | 9.09 | 144,726.50 | -99.96 | -80.65 | -157.15 | -224.84 | 20.90 | -- | -545.95 | -948.54 | 0.3864 | -- | 0.1602 | -- | 187.51 | 367.97 | -28.00 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -18.35m | 7.03m | 21.00 | -- | 0.1902 | -- | -- | -1.15 | -1.15 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -28.88 | -36.95 | -32.40 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0056 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
| Tenax Therapeutics Inc | 0.00 | -7.71m | 7.05m | 5.00 | -- | 0.1326 | -- | -- | -33.51 | -33.51 | 0.00 | 27.15 | 0.00 | -- | -- | 0.00 | -102.20 | -199.16 | -159.72 | -285.64 | -- | -- | -- | -- | -- | -82.13 | 0.0583 | -- | -- | -- | 30.21 | -- | -- | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -48.93m | 7.06m | 22.00 | -- | 1.11 | -- | -- | -12.41 | -12.41 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -124.91 | -61.43 | -150.17 | -68.82 | -- | -- | -- | -- | -- | -4,784.14 | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
| Plus Therapeutics Inc (USA) | 4.91m | -13.32m | 7.12m | 20.00 | -- | -- | -- | 1.45 | -4.51 | -4.51 | 1.57 | -0.3033 | 0.2787 | -- | -- | 245,650.00 | -75.54 | -59.18 | -210.10 | -133.04 | -- | -- | -271.04 | -470.45 | -- | -- | 1.51 | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -5.09m | 7.24m | 3.00 | -- | 14.64 | -- | -- | -2.77 | -2.77 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -103.09 | -104.18 | -111.07 | -111.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 19.41 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Protagenic Therapeutics Inc's reporting currency: US Dollar USD
2.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 32.00k | 0.72% |
| Geode Capital Management LLCas of 31 Dec 2023 | 25.20k | 0.57% |
| FNY Capital Management LPas of 31 Dec 2023 | 18.75k | 0.42% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 13.81k | 0.31% |
| G1 Execution Services LLCas of 31 Dec 2023 | 13.20k | 0.30% |
| Tower Research Capital LLCas of 31 Dec 2023 | 9.03k | 0.20% |
| Vanguard Global Advisers LLCas of 31 Dec 2023 | 1.17k | 0.03% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Dec 2023 | 26.00 | 0.00% |
| CWM LLCas of 31 Mar 2024 | 1.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 1.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
